Funding Alert Archives - EverGlade Consulting

Funding Alert

Gene therapy

EverGlade Consulting Helps Cirsium Secure up to $61 Million in ARPA-H Funding

Leave a Comment / ARPA-H, EverGlade Insights / By

EverGlade Consulting, a national consulting firm, has helped Cirsium Biosciences successfully secure up to $61 million in funding to create a rapid, safe, scalable, and low-cost plant-based manufacturing platform to drastically reduce production time and cost of viral vector-based gene therapies. How Funding Will Be Used The $61 million in ARPA-H funding will enable Cirsium […]

EverGlade Consulting Helps Cirsium Secure up to $61 Million in ARPA-H Funding Read More »

technology to identify novel antigens

DTRA MCDC RAIIC Funding Opportunity

Leave a Comment / DTRA, EverGlade Insights / By

Final-draft-SOO-RAIIC The Joint Science and Technology Office (JSTO) Defense Threat Reduction Agency (DTRA) has announced an upcoming funding opportunity for members of the Medical CBRN Defense Consortium (MCDC) to develop technologies that can accelerate the identification and immune profile of novel antigens in emerging infectious diseases (EID). JSTO intends to incorporate the final technology into

DTRA MCDC RAIIC Funding Opportunity Read More »

compact wearable vaccine monitoring

DTRA Issues Draft SOO for Continual Blood Sampling Technology

Leave a Comment / DTRA, EverGlade Insights / By

Final-Draft-SOO-IMMIR The Joint Science and Technology Office (JSTO) within the Defense Threat Reduction Agency (DTRA) has announced an upcoming funding opportunity for members of the Medical CBRN Defense Consortium (MCDC). The objective of the IMMIR solicitation is to develop innovative technologies for vaccine monitoring via a compact wearable device that can analyze minute blood samples.

DTRA Issues Draft SOO for Continual Blood Sampling Technology Read More »

Artificial Intelligence (AI) and Machine Learning (ML) innovations

DARPA Releases Strategic Catalyst Announcement for AI BTO

Leave a Comment / DARPA, EverGlade Insights, Time Sensitive / By

DARPA-SCA-24-01 The Biological Technologies Office (BTO) of the Defense Advanced Research Projects Agency (DARPA) recently released a Strategic Catalyst Announcement (SCA) titled AI BTO (Funding Opportunity Number: DARPA-SCA-24-01). AI BTO encourages participation by new or non-traditional proposers to leverage Artificial Intelligence (AI) and Machine Learning (ML) innovations for the BTO. Overview of AI BTO AI

DARPA Releases Strategic Catalyst Announcement for AI BTO Read More »

BARDA Issues Amendment 4 to BAA for Medical Countermeasures R&D

BARDA Issues Amendment 4 to BAA for Medical Countermeasures R&D 

Leave a Comment / BARDA, EverGlade Insights / By

BARDA has recently unveiled significant updates to its BAA, emphasizing a more refined and responsive approach to public health preparedness. Amendment 4 introduces crucial changes to the Areas of Interest designed to align BARDA’s efforts with the evolving landscape of global health threats.

BARDA Issues Amendment 4 to BAA for Medical Countermeasures R&D  Read More »

NIH Funding

New NIH Funding Opportunity – Investigating the Role of Genomic Variation on Gene Regulation and Disease

Leave a Comment / EverGlade Insights, NIH / By

At EverGlade Consulting, we are always on the lookout for new funding opportunities that can help our clients advance their research and development goals. Today, we’re excited to inform you about a new Request for Applications (RFA) from the National Institutes of Health (NIH): RFA-HG-24-004.

New NIH Funding Opportunity – Investigating the Role of Genomic Variation on Gene Regulation and Disease Read More »

Scroll to Top